The Challenge
Alpha Antitrypsin Deficiency (Alpha-1) is a hereditary disease in which the body lacks an important protein, often leading to the development of emphysema or COPD. It’s estimated that one in every 2,500 Americans have Alpha-1 and could benefit from augmentation therapy derived from the blood plasma of healthy human donors to help increase the levels of Alpha-1 in their blood and lungs.
Contrast Creative partnered with Grifols, one of the leading manufacturers of plasma medications, to produce a video that would be shown in 150 of Grifols plasma donation centers across the country. This video interviews three patients with Alpha-1 to help educate plasma donors on this disease and highlight the need for continued plasma donations to make their augmentation therapies. November, 2013 marked the 50th anniversary of the identification of alpha antitrypsin protein, and the 25th anniversary of the creation of augmentation therapy to help treat this condition. Designed to help increase awareness about Alpha-1 and the need for plasma to make vital therapies for this condition, this video would also serve as a tool to thank donors, encourage their recommitment to the donation process and commemorate these crucial milestones in the history of Alpha-1.
The Result
These stories were shown in 150 Grifols donor centers all across the United States during the month of November. An additional version of the video will be distributed to donor centers to be viewed throughout the year.